Related Experiment Video

Updated: Sep 20, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.4K

PI3Kδ as a Novel Therapeutic Target for Aggressive Prostate Cancer

Bi-Dar Wang1,2, Alyssa Lucero1, Siyoung Ha1

  • 1Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA.

Cancers
|May 28, 2025
PubMed

Insights

Phosphoinositide 3-kinases delta (PI3Kδ) drives prostate cancer progression and immune suppression. Targeting PI3Kδ offers a promising therapeutic strategy for improving treatment outcomes in prostate cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Phosphoinositide 3-kinases (PI3Ks) signaling is crucial for cellular functions and frequently dysregulated in cancers.
  • PI3Kδ, a class IA PI3K, is overexpressed in leukocytes and solid tumors, including prostate cancer.
  • PI3Kδ plays a significant role in tumorigenesis and immune suppression within the tumor microenvironment.

Purpose of the Study:

  • To comprehensively review the functional mechanisms of PI3Kδ in prostate cancer progression and immune regulation.
  • To summarize preclinical and clinical studies of PI3Kδ-targeted inhibitors.
  • To discuss novel therapeutic strategies and challenges for PI3Kδ-based prostate cancer therapies.

Main Methods:

  • Literature review of functional mechanisms of PI3Kδ in prostate cancer.
  • Summary of preclinical and clinical studies on PI3Kδ inhibitors.
  • Analysis of combination therapies involving PI3Kδ inhibitors.

Main Results:

  • PI3Kδ drives tumor progression and creates a suppressive tumor microenvironment in prostate cancer.
  • PI3Kδ splice isoforms contribute to tumor aggressiveness and treatment resistance.
  • PI3Kδ inhibitors show potential as single agents and in combination therapies.

Conclusions:

  • PI3Kδ is a critical therapeutic target for prostate cancer.
  • Targeted inhibition of PI3Kδ, alone or in combination, holds promise for improving treatment efficacy.
  • Further research is needed to overcome limitations and challenges in PI3Kδ-based therapies.
Keywords:
PI3K/AKT/mTOR signalingPI3Kδ and pan-PI3K inhibitorsandrogen receptor inhibitorscombination therapiesimmune checkpoint blockersphosphoinositide 3-kinases delta (PI3Kδ)splice isoformstumor immune microenvironment

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K